It has absolutely nothing to do with capital. The company is well funded.
There are currently 3 sites activated. Scott has mentioned several times in previous presentations and updates that it was always going to be a staggered approach. This is our pivotal trial for FDA submission, we want to get this right. A staggered approach not only minimises risk but also has strategic benefits.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
0.010(0.56%) |
Mkt cap ! $153.9M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.85 | $1.80 | $63.18K | 34.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 738 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.85 | 9580 | 2 |
View Market Depth
| Last trade - 10.45am 16/06/2025 (20 minute delay) ? |
| EMV (ASX) Chart |